NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas

Antioxidants and Redox Signaling

Volumn 26, Issue 15, 2017, Pages 864-877

  Azouzi, Naïma ^a,b,c   Cailloux, Jérémy ^a,b   Cazarin, Juliana M ^a,b,d   Knauf, Jeffrey A ^e   Cracchiolo, Jennifer ^e   Al Ghuzlan, Abir ^a,b   Hartl, Dana ^a   Polak, Michel ^f,g,h,i   Carré, Aurore ^f,g   El Mzibri, Mohammed ^c   Filali Maltouf, Abdelkarim ^j   Al Bouzidi, Abderrahmane ^k   Schlumberger, Martin ^a,b   Fagin, James A ^e   Ameziane El Hassani, Rabii ^a,c   Dupuy, Corinne ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CENTRE NATIONAL DE L ENERGIE DES SCIENCES TECHNIQUES NUCLEAIRES   (Morocco)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f INSTITUT COCHIN   (France)

^g IMAGINE INSTITUTE   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j FACULTÉ DES SCIENCES   (Morocco)

^k MOHAMMED V UNIVERSITY   (Morocco)

more..

Author keywords

BRAFV600E; NADPH oxidase; NIS; NOX4; papillary thyroid cancer; ROS

Indexed keywords

B RAF KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMAD3 PROTEIN; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; TRANSFORMING GROWTH FACTOR BETA; VEMURAFENIB; BRAF PROTEIN, HUMAN; COTRANSPORTER; MESSENGER RNA; NOX4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; THYROID CELL; THYROID PAPILLARY CARCINOMA; UPREGULATION; ANIMAL; GENETICS; METABOLISM; PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR CELL CULTURE;

ANIMALS; CARCINOMA, PAPILLARY; DOWN-REGULATION; FEMALE; HUMANS; MALE; MICE; NADPH OXIDASE 4; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; SYMPORTERS; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 85018916289     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6616     Document Type: Article

References (53)

1. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941, 2004.
2. Ameziane-El-Hassani R, Talbot M, de Souza Dos Santos MC, Al Ghuzlan A, Hartl D, Bidart JM, De Deken X, Miot F, Diallo I, de Vathaire F, Schlumberger M, Dupuy C. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci USA 112: 5051-5056, 2015.
3. Barnes JL and Gorin Y. Myofibroblast differentiation during fibrosis: Role of NAD(P)H oxidases. Kidney Int 79: 944-956, 2011.
4. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
5. Boudreau HE, Casterline BW, Burke DJ, Leto TL. Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-b-mediated migration of human lung and breast epithelial cells. Br J Cancer 110: 2569-2582, 2014.
6. Boudreau HE, Casterline BW, Rada B, Korzeniowska A, Leto TL. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 53: 1489-1499, 2012.
7. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159: 676-690, 2014.
8. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121: 4700-4711, 2011.
9. Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci USA 106: 7979-7984, 2009.
10. Choi YW, Kim HJ, Kim YH, Park SH, Chwae YJ, Lee J, Soh EY, Kim JH, Park TJ. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. Exp Mol Med 46: E120, 2014.
11. Costamagna E, Garcia B, Santisteban P. The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factorbeta repression of the sodium/iodide symporter gene. J Biol Chem 279: 3439-3446, 2004.
12. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059-2067, 2008.
13. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 379: 458-460, 1996.
14. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108: 1615-1620, 2011.
15. Garcia-Rendueles ME, Ricarte Filho JC, Untch B, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA. NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discov 5: 1178-1193, 2015.
16. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L. Woodruff JM, Berns A, Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14: 1617-1630, 2000.
17. Grubeck-Loebenstein B, Buchan G, Sadeghi R, Kissonerghis M, Londei M, Turner M, Pirich K, Roka R, Niederle B, Kassal H, Waldhaüsl W, Feldmann M. Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. J Clin Invest 83: 764-770, 1989.
18. Hayes P and Knaus UG. Balancing reactive oxygen species in the epigenome: NADPH oxidases as target and perpetrator. Antioxid Redox Signal 18: 1937-1945, 2013.
19. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368: 623-632, 2013.
20. Hsieh CH, Wu CP, Lee HT, Liang JA, Yu CY, Lin YJ. NADPH oxidase subunit 4 mediates cycling hypoxiapromoted radiation resistance in glioblastoma multiforme. Free Radical Bio Med 53: 649-658, 2012.
21. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 69: 597-607, 2006.
22. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425, 2001.
23. Kambe F, Nomura Y, Okamoto T, Seo H. Redox regulation of thyroid-transcription factors, Pax-8 and TTF-1, is involved in their increased DNA-binding activities by throtropin in rat thyroid FRTL-5 cells. Mol Endocrinol 10: 801-812, 1996.
24. Kawaguchi A, Ikeda M, Endo T, Kogai T, Miyazaki A, Onaya T. Transforming growth factor-beta1 suppresses thyrotropin-induced Nasymporter messenger RNA and protein levels in FRTL-5 rat thyroid cells. Thyroid 7: 789-794, 1997.
25. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30: 3153-3162, 2011.
26. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306, 2006.
27. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S. Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39: 212-216, 2004.
28. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93: 2194-2201, 2008.
29. Levy O, De la Vieja A, Ginter CS, Riedel C, Dai G, Carrasco N. N-linked glycosylation of the thyroid Na (NIS). Implications for its secondary structure model. J Biol Chem 273: 22657-22663, 1998.
30. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22: 668-682, 2012.
31. Matoba H, Sugano S, Yamaguchi N, Miyachi Y. Expression of transforming growth factor-beta1 and transforming growth factor-beta Type-II receptor mRNA in papillary thyroid carcinoma. Horm Metab Res 30: 624-628, 1998.
32. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, Marais R, Pritchard C. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65: 11493-11500, 2005.
33. Mishra PK, Raghuram GV, Jain D, Jain SK, Khare NK, Pathak N. Mitochondrial oxidative stress-induced epigenetic modifications in pancreatic epithelial cells. Int J Toxicol 33: 116-129, 2014.
34. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr., Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473, 2005.
35. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3: 520-533, 2013.
36. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-beta signaling during epithelialmesenchymal transformation: Implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179: 11-23, 2005.
37. Nicolussi A, D'Inzeo S, Santulli M, Colletta G, Coppa A. TGF-beta control of rat thyroid follicular cells differentiation. Mol Cell Endocrinol 207: 1-11, 2003.
38. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: What is it really orchestrating in thyroid cancer? Oncotarget 1: 751-756, 2010.
39. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL, Baylin SB. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, polycomb members to promoter CpG Islands. Cancer Cell 20: 606-619, 2011.
40. Pardali K and Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62, 2007.
41. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69: 8317-8325, 2009.
42. Stephen JK, Chitale D, Narra V, Chen KM, Sawhney R, Worsham MJ. DNA methylation in thyroid tumorigenesis. Cancers (Basel) 3: 1732-1743, 2011.
43. Szinnai G, Lacroix L, Carré A, Guimiot F, Talbot M, Martinovic J, Delezoide AL, Vekemans M, Michiels S, Caillou B, Schlumberger M, Bidart JM, Polak M. Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus. J Clin Endocrinol Metab 92: 70-76, 2007.
44. Taton M, Lamy F, Roger PP, Dumont JE. General inhibition by transforming growth factor beta 1 of thyrotropin and cAMP responses in human thyroid cells in primary culture. Mol Cell Endocrinol 95: 13-21, 1993.
45. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol 1: E59, 2003.
46. Tsushima T, Arai M, Saji M, Ohba Y, Murakami H, Ohmura E, Sato K, Shizume K. Effects of transforming growth factor-beta on deoxyribonucleic acid synthesis and iodine metabolism in porcine thyroid cells in culture. Endocrinology 123: 1187-1194, 1988.
47. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA104: 2803-2808, 2007.
48. Weyemi U, Caillou B, Talbot M, Ameziane-El-Hassani R, Lacroix L, Lagent-Chevallier O, Al Ghuzlan A, Roos D, Bidart JM, Virion A, Schlumberger M, Dupuy C. Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr Relat Cancer 17: 27-37, 2010.
49. Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, Caillou B, Talbot M, Dardalhon M, Al Ghuzlan A, Bidart JM, Schlumberger M, Dupuy C. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 31: 1117-1129, 2012.
50. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
51. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309: 1493-1501, 2013.
52. Yamaura M, Mitsushita J, Furuta S, Kiniwa Y, Ashida A, Goto Y, Shang WH, Kubodera M, Kato M, Takata M, Saida T, Kamata T. NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res 69: 2647-2654, 2009.
53. Zavadil J and Böttinger EP. TGF-beta and epithelial-tomesenchymal transitions. Oncogene 24: 5764-5774, 2005.